A randomized Phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2530-2535

  Tolcher, Anthony W ^a   Reyno, Leonard ^b   Venner, Peter M ^c   Ernst, Scott D ^d   Moore, Malcolm ^e   Geary, Richard S ^f   Chi, Kim ^a   Hall, Sean ^g   Walsh, Wendy ^g   Eisenhauer, Elizabeth ^g  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b JURAVINSKI CANCER CENTRE   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f ISIS PHARMACEUTICALS   (United States)

^g Institut national du cancer du Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CGP 69846A; HORMONE; ISIS 3521; ANTISENSE OLIGODEOXYNUCLEOTIDE; ISOENZYME; NUCLEOTIDE; PRKCA PROTEIN, HUMAN; PROTEIN KINASE C; PROTEIN KINASE C ALPHA; RAF PROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; FATIGUE; GAIT DISORDER; HEADACHE; HORMONAL THERAPY; HUMAN; MALE; NAUSEA; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; SYMPTOM; THROMBOCYTOPENIA; CELL DIVISION; DRUG ANTAGONISM; METABOLISM; METASTASIS; MIDDLE AGED; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CELL DIVISION; HUMAN; ISOENZYMES; MALE; MIDDLE AGE; NEOPLASM METASTASIS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-RAF; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SUPPORT, NON-U.S. GOV'T; THIONUCLEOTIDES; TREATMENT OUTCOME; HUMANS; MIDDLE AGED; PROTEIN KINASE C-ALPHA;

EID: 0036023413     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
2. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
3. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis
4. The function of GRB2 in linking the insulin receptor to Ras signaling pathways
5. Activation of Ras by receptor tyrosine kinases
6. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes
7. Interaction of the protein kinase Raf-I with 14-3-3 proteins
8. Activation of human raf transforming genes by deletion of normal amino-terminal coding sequences
9. Ras oncogenes in human cancer: A review
10. Protein kinase C α activates RAF-1 by direct phosphorylation
11. Bcl-2 targets the protein kinase Raf-1 to mitochondria
12. Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1
13. bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
14. Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue
15. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas
16. 12(S)-HETE enhancement of prostate tumor cell invasion: Selective role of PKC α
17. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer
18. The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells
19. c-fos promoter insensitivity to phorbol ester and possible role of protein kinase C in androgen-independent cancer cells
20. Transforming growth factor-β1 inhibits membrane association of protein kinase C α in a human prostate cancer cell line, PC3
21. Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase cα
22. The potential of protein kinase C as a target for anticancer treatment
23. Antisense oligonucleotides as inhibitors of signal transduction: Development from research tools to therapeutic agents
24. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides
25. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribo-nucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo
26. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
27. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-α, in patients with advanced cancer
28. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer
29. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer
30. Quantitation of phosphorothioate oligonucleotides in human plasma
31. Multinomial phase II cancer trials incorporating response and early progression
32. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression
33. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A)
34. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
35. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice
36. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice
37. Phase I/II trial of ISIS 3521, and antisense inhibitor of PKC-α with carboplatin and paclitaxel in non-small cell lung cancer